Overview
Mixed pancreatic endocrine tumors (PNETs) represent a subset of neuroendocrine neoplasms characterized by the presence of multiple hormone-producing cell types within the same tumor, complicating diagnosis and treatment strategies. 23Diagnosis
Imaging Studies: Utilize CT, MRI, and functional imaging (e.g., somatostatin receptor scintigraphy) for initial assessment and differentiation from other pancreatic cystic tumors. 2
Histopathology: Essential for confirming neuroendocrine origin and grading via Ki-67 index and morphological features. 34
Immunohistochemistry: Evaluate for somatostatin receptor (SSTR) expression, particularly SSTR-2a, which correlates with better survival outcomes. 3
Differential Diagnosis: Distinguish from cystic neoplasms like mucinous and serous cystic neoplasms, requiring careful imaging and pathological analysis. 2Management
Surgical Resection: Primary treatment for localized disease, aiming for complete tumor removal. 4
Somatostatin Analogues: Consider for symptom control and potential stabilization in inoperable cases, though specific dosing is not detailed in the abstracts. 3
Targeted Therapy: Palbociclib may be considered in low-grade PNETs based on emerging evidence, though specific to certain subtypes and requires further validation. 1
Radiation Therapy: Adjunctive role in cases with unresectable disease or recurrence, though specifics are not detailed in the provided abstracts.
Supportive Care: Manage symptoms related to hormone excess and address complications post-surgery, such as gastrosplenic circulation changes post-distal pancreatectomy. 5Special Populations
Elderly Patients: Consider functional status and comorbidities when planning surgical interventions; survival outcomes may vary. 4
Comorbidities: Presence of distant disease at diagnosis correlates with poorer outcomes, necessitating tailored management strategies. 4Key Recommendations
Surgical resection is recommended for localized mixed PNETs to improve survival outcomes. (Evidence: Strong 4)
Evaluate SSTR-2a expression preoperatively or pathologically as it is a stronger predictor of survival compared to Ki-67 index. (Evidence: Moderate 3)
Consider somatostatin analogues for symptom management in patients with inoperable or advanced disease, though evidence is evolving. (Evidence: Moderate 3)
Monitor splenic function post-distal pancreatectomy with spleen preservation due to potential hypoperfusion and functional decline. (Evidence: Weak 5)References
1 Grande E, Molina-Cerrillo J, Alonso-Gordoa T. In Reply. The oncologist 2020. link
2 Dąbkowski K, Kos-Kudła B, Andrysiak-Mamos E, Syrenicz A, Pilch-Kowalczyk J, Starzyńska T. Cystic pancreatic neuroendocrine tumours - a gastroenterologist's point of view. Endokrynologia Polska 2018. link
3 Mehta S, de Reuver PR, Gill P, Andrici J, D'Urso L, Mittal A et al.. Somatostatin Receptor SSTR-2a Expression Is a Stronger Predictor for Survival Than Ki-67 in Pancreatic Neuroendocrine Tumors. Medicine 2015. link
4 Boyar Cetinkaya R, Vatn M, Aabakken L, Bergestuen DS, Thiis-Evensen E. Survival and prognostic factors in well-differentiated pancreatic neuroendocrine tumors. Scandinavian journal of gastroenterology 2014. link
5 Kohan G, Ocampo CG, Zandalazini HI, Klappenbach R, Quesada BM, Porras LT et al.. Changes in gastrosplenic circulation and splenic function after distal pancreatectomy with spleen preservation and splenic vessel excision. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2013. link
6 Berendt RC, Shnitka TK, Wiens E, Manickavel V, Jewell LD. The osteoclast-type giant cell tumor of the pancreas. Archives of pathology & laboratory medicine 1987. link